| To: Miljenko Zuanic who wrote (3115) | 1/29/2018 4:43:40 PM | | From: nigel bates | | | | I would guess quite a number will leave.
By all accounts, Ablynx seems to have been a great place to work; whether it stays that for long as part of big pharma seems a bit unlikely. Just guessing, though. |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Miljenko Zuanic | 1/31/2018 5:53:16 PM | | | | | | RE: VRTX
"Stock Repurchase Program"
<The company today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of common stock through December 31, 2019. The repurchase program is expected to be executed over two years with the primary objective of reducing the impact of dilution from employee equity programs.
Purchases may be made through the open market or privately negotiated transactions and may be made pursuant to Rule 10b5-1 plans or other means as determined by Vertex's management and in accordance with the requirements of the Securities and Exchange Commission.>
Am I reading this corrects, they are AWARDING insiders (management, BofD) with $500M bonus, in options and/or free shares ??? |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: DewDiligence_on_SI who wrote (3119) | 1/31/2018 7:47:31 PM | | From: Miljenko Zuanic | | | | <..privately negotiated transactions and may be made pursuant to Rule 10b5-1 plans...>
You may see it as facetious (in one way it was), but the company is signaling that they will/may be buying shares from insiders, after they convert options to shares according to 10b5-1 plan. But if they want to award SH, distribute $500M to them (or spent on R&D, or distribute to "Ms. Maria ", who is brooming a floor at company, for living) , and cut down on options award as measure for controlling/offset dilution.
Will they disclose or hide purchase price, from insiders? |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: DewDiligence_on_SI who wrote (3121) | 1/31/2018 11:28:51 PM | | From: Miljenko Zuanic | | | | It is for the open market, as well for negotiated private transactions, that is related to 10b5-1.
For years VRTX sucked money out of SH, increasing shares count (also by dilution from options/awards). Cumulative they still did not capture capital investment,... they are still negative,....they still have $5B in accumulated deficit, so current EXCESS cash is (in majority) from STOCK offering AND OTHER DILUTIVE FINANCING, not EARNING FROM BUSINESS.
Everyone need bit of luck in this business, when they have nothing left they turned toward CF...and they have game changing candidates. Great, for years management and boards have financial benefits, now SH can benefit from appreciated SP. But, if the want to award anyone, cash should be distributed to SH as one time dividend or something similar. And, if BofD want to thanks SH for long standing support by controlling and reducing dilution, ...well they can ask management to rip 1.2M shares from their options awards.
PS: This is not related only to VRTX, to many bios, old and new. |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: DewDiligence_on_SI who wrote (3121) | 1/31/2018 11:51:27 PM | | From: Miljenko Zuanic | | | | <The 10b5-1 plan VRTX is talking about in the PR is for the company's own buybacks on the open market;.
I guess, I did not read this correctly in first place. Are you saying that company as entity can have their own ?
northerntrust.com
I am confused here. Why company, as entity, can not do buy back on "as seen fit" schedule, even when they have material information? For instance, price is underappreciated, and they have positive data on candidate (that can paint business picture more pink)? |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Miljenko Zuanic who wrote (3123) | 2/1/2018 8:14:37 AM | | From: DewDiligence_on_SI | | | | | Yes, it's the company's own 10b5-1 (buying) plan. It's not necessary to have a 10b5-1 plan to buy company shares on the open market, but some companies prefer to set up a 10b5-1 with an investment bank, rather than handling the task internally, to remove any appearance of impropriety. |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: nigel bates | 2/16/2018 5:20:43 AM | | | | | | Sanofi further committing to develop nanobodies with Ablynx:
GHENT, Belgium, 16 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Sanofi has exercised its option to license two additional target combinations as part of the research collaboration signed in July 2017, focussed on developing and commercialising Nanobody®-based therapeutics for the treatment of various immune-mediated inflammatory diseases.
Under the terms of the agreement, Sanofi gains exclusive global rights to two additional multi-specific Nanobodies against selected targets and in return will pay Ablynx exercise fees totalling €13 million plus additional research funding. Multi-specific Nanobodies provide the ability to address different pathway or disease targets with one therapeutic molecule. Ablynx has already received an upfront payment totalling €23 million, together with research funding under this collaboration.
Sanofi will be responsible for the development, manufacturing and commercialisation of any products resulting from this agreement comprising up to eight programmes. Ablynx will be eligible to receive development, regulatory and commercial milestone payments of up to €2.4 billion plus tiered royalties up to low double digits on the net sales of any products originating from the collaboration... |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
